Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours (Q44425475)

2 December 2017

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours (English)

1 reference

2 December 2017

Samer Ezziddin

1

1 reference

2 December 2017

Feras Khalaf

2

1 reference

2 December 2017

Maria Vanezi

3

1 reference

2 December 2017

Torjan Haslerud

4

1 reference

2 December 2017

Karin Mayer

5

1 reference

2 December 2017

Abdullah Al Zreiqat

6

1 reference

2 December 2017

Winfried Willinek

7

1 reference

2 December 2017

Hans-Jürgen Biersack

8

1 reference

2 December 2017

Amir Sabet

9

1 reference

2 December 2017

7 February 2014

1 reference

2 December 2017

9

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

2 December 2017

41

1 reference

2 December 2017

5

1 reference

2 December 2017

925-933

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-013-2677-3

2 December 2017

0 references

cites work

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2677-3

Chemotherapy of endocrine malignancies: a review.

21 January 2018

1 reference

12 December 2020

Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

12 December 2020

Promising advances in the treatment of malignant pancreatic endocrine tumors

1 reference

12 December 2020

The ENETS guidelines: the new TNM classification system

1 reference

12 December 2020

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

12 December 2020

Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

1 reference

12 December 2020

Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

10.1007/S00259-013-2677-3

Identifiers

DOI

1 reference

2 December 2017

1 reference